Legislation on information to patients in the EU - will it be worth the effort?
This article was originally published in SRA
Executive Summary
Yet more work for the European Medicines Agency and yet more fees levied on the pharmaceutical industry. Those will be sure consequences of the legal framework that is likely to result from the European Commission's newly released amended proposals on the information pharmaceutical companies can provide to patients about their prescription drugs. It is not so clear what the benefits will be to patients.